mGluR4 orthosteric agonists have been tested in neurotoxin-based rat models of PD, where they reduced signs of inflammation and the consequent dopamine neuronal loss (Battaglia et al., 2006; Zhou et al., 2006; Betts et al., 2012). This evidence concerns the gene GRM4 and Parkinson disease.